Market cap
$54 Mln
Recently Viewed
Clear All$4.14
$-0.22
(-5.05%)
As on 30-Aug-2022 16:00EDT
Market cap
$54 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-9 Mln
ROE
-0.1 %
ROCE
-- %
Industry P/E
53.55
EV/EBITDA
0.2
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
13,136,400
CFO
$-202.86 Mln
EBITDA
$-224.18 Mln
Net Profit
$-239.74 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Second Sight Medical Products (EYES)
| -15.3 | -23.3 | -36.6 | -63.5 | -38.6 | -30.8 | -- |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Second Sight Medical Products (EYES)
| -12.8 | -68.5 | -16.2 | -53.4 | -3.0 | -66.6 | -42.6 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
As of August 30, 2022, Second Sight Medical Products, Inc. was acquired by Nano Precision Medical, Inc., in a reverse merger transaction. Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are... intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California. Read more
Acting Chief Exec. Officer
Mr. Scott Dunbar
Acting Chief Exec. Officer
Mr. Scott Dunbar
Headquarters
Sylmar, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Second Sight Medical Products Inc (EYES) is $4.14 (NASDAQ) as of 30-Aug-2022 16:00 EDT. Second Sight Medical Products Inc (EYES) has given a return of -38.59% in the last 3 years.
Since, TTM earnings of Second Sight Medical Products Inc (EYES) is negative, P/E ratio is not available.
The P/B ratio of Second Sight Medical Products Inc (EYES) is 0.86 times as on 30-Aug-2022, a 74 discount to its peers’ median range of 3.27 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Second Sight Medical Products Inc (EYES) are Rs -- and Rs -- as of 24-Apr-2026.
Second Sight Medical Products Inc (EYES) has a market capitalisation of $ 54 Mln as on 30-Aug-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Second Sight Medical Products Inc (EYES), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.